Regulation of intracellular cardiomyocyte calcium stores by peptides: A new approach to cardiac protection

Current Medicinal Chemistry

Volumn 19, Issue 34, 2012, Pages 5782-5792

  Gallina, C ^a   Brero, A ^a   Gallo, M P ^a   Levi, R ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Calcium; Cardioprotection; ErbB; Excitation contraction coupling; Heart; Mitrochondria; Neuregulin; RISK; Sarcoplasmic reticulum; Signal transduction; Urocortin

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ANTHRACYCLINE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM ION; CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; LAPATINIB; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NATRIURETIC FACTOR; NEU DIFFERENTIATION FACTOR; PEPTIDE; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; RYANODINE RECEPTOR; RYANODINE RECEPTOR 2; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; SODIUM CALCIUM EXCHANGE PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROCORTIN I; UROCORTIN II; UROCORTIN III; VOLTAGE GATED CHANNEL FORMING PROTEIN;

BREAST CANCER; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CARDIOTOXICITY; CONGESTIVE CARDIOMYOPATHY; DRUG MECHANISM; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE RELAXATION; HEART PROTECTION; HUMAN; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL TOXICITY; NONHUMAN; PROTEIN PROCESSING; REPERFUSION INJURY; REVIEW; SARCOLEMMA; SARCOPLASMIC RETICULUM; SUMOYLATION;

CALCIUM; CALCIUM SIGNALING; HUMANS; MITOCHONDRIA; MYOCYTES, CARDIAC; NEUREGULIN-1; PEPTIDES; RECEPTOR, ERBB-2; SARCOPLASMIC RETICULUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; UROCORTINS;

EID: 84871656632     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712804143295     Document Type: Review

References (155)

1. Hauptman, P. J.; Kelly, R. A., Digitalis. Circulation, 1999, 99, (9), 1265-1270.
2. Ritter, G.; Dembicki, E. L., The herbal history of Digitalis: lessons for alternative medicine. JAMA, 2000, 283, (7), 884-886.
3. Fulton, J. F., Charles Darwin (1758-1778) and the history of the early use of digitalis. 1934. J. Urban Health, 1999, 76, (4), 533-541.
4. Norman, J. N., William Withering and the purple foxglove: a bicentennial tribute. J. Clin. Pharmacol., 1985, 25, (7), 479-483.
5. Bers, D. M., Calcium cycling and signaling in cardiac myocytes. Ann. Rev. Physiol., 2008, 70, 23-49.
6. Bers, D. M., Calcium fluxes involved in control of cardiac myocyte contraction. Circ. Res., 2000, 87, (4), 275-281.
7. Bootman, M. D.; Smyrnias, I.; Thul, R.; Coombes, S.; Roderick, H. L., Atrial cardiomyocyte calcium signalling. BBA-Mol. Cell. Res., 2011, 1813, (5), 922-934.
8. Smyrnias, I.; Mair, W.; Harzheim, D.; Walker, S. A.; Roderick, H. L.; Bootman, M. D., Comparison of the T-tubule system in adult rat ventricular and atrial myocytes, and its role in excitation contraction coupling and inotropic stimulation. Cell. Calcium, 2010, 47, (3), 210-223.
9. Lakatta, E. G.; Maltsev, V. A.; Vinogradova, T. M., A coupled SYSTEM of intracellular Ca2+ clocks and surface membrane voltage clocks controls the timekeeping mechanism of the heart's pacemaker. Circ. Res., 2010, 106, (4), 659-673.
10. Difrancesco, D.; Noble, D., The funny current has a major pacemaking role in the sinus node. Heart Rhythm, 2012, 9(2), 299-301.
11. Lakatta, E. G.; Difrancesco, D., What keeps us ticking: a funny current, a calcium clock, or both? J. Mol. Cell. Cardiol., 2009, 47, (2), 157-170.
12. Greiser, M.; Lederer, W. J.; Schotten, U., Alterations of atrial Ca2+ handling as cause and consequence of atrial fibrillation. Cardiovas. Res., 2011, 89, (4), 722-733.
13. Josephson, I. R.; Guia, A.; Sobie, E. A.; Lederer, W. J.; Lakatta, E. G.; Stern, M. D., Physiologic gating properties of unitary cardiac L-type Ca2+ channels. Biochem. Biophys. Res. Commun., 2010, 396, (3), 763-766.
14. Grandi, E.; Morotti, S.; Ginsburg, K.; Severi, S.; Bers, D., Interplay of voltage and Ca-dependent inactivation of L-type Ca current. Prog. Biophys. Mol. Biol., 2010, 103, (1), 44-50.
15. Fabiato, A., Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am. J. Physiol. - Cell. Physiol., 1983, 245, (1), C1-C14.
16. Shiels, H. A.; Di Maio, A.; Thompson, S.; Block, B. A., Warm fish with cold hearts: thermal plasticity of excitation-contraction coupling in bluefin tuna. Proc. Royal. Soc. B-Biolog. Sci., 2010, 278, (1702), 18-27.
17. Vornanen, M.; Shiels, H. A.; Farrell, A. P., Plasticity of excitation-contraction coupling in fish cardiac myocytes. Compar. Biochem. Physiol. - Part. A:. Mol. & Integr. Physiol., 2002, 132, (4), 827-846.
18. Gómez, A. M.; Valdivia, H. H.; Cheng, H.; Lederer, M. R.; Santana, L. F.; Cannell, M. B.; McCune, S. A.; Altschuld, R. A.; Lederer, W. J., Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science (New York, NY), 1997, 276, (5313), 800-806.
19. Hu, S.-T.; Liu, G.-S.; Shen, Y.-F.; Wang, Y.-L.; Tang, Y.; Yang, Y.-J., Defective Ca (2+) handling proteins regulation during heart failure. Physiol. Res./Acad. Scient. Bohemosl., 2011, 60, (1), 27-37.
20. Kandilci, H. B.; Tuncay, E.; Zeydanli, E. N.; Sozmen, N. N.; Turan, B., Agerelated regulation of excitation-contraction coupling in rat heart. J. Physiol. Biochem., 2011, 67, (3), 317-330.
21. Lanner, J. T.; Georgiou, D. K.; Joshi, A. D.; Hamilton, S. L., Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harbor. Perspect. Biol., 2010, 2, (11), a003996.
22. Marks, A. R.; Priori, S.; Memmi, M.; Kontula, K.; Laitinen, P. J., Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia. J. Cell. Physiol., 2002, 190, (1), 1-6.
23. Bers, D. M., Cardiac excitation-contraction coupling. Nature, 2002, 415, (6868), 198-205.
24. Lederer, W.; Cannell, M.; Cohen, N.; Berlin, J., Excitation-contraction coupling in heart muscle. Mol. Cell. Biochem., 1989, 89, (2), 115-119.
25. Sobie, E. A.; Guatimosim, S.; Gomez-Viquez, L.; Song, L. S.; Hartmann, H.; Saleet Jafri, M.; Lederer, W. J., The Ca 2+ leak paradox and rogue ryanodine receptors: SR Ca 2+ efflux theory and practice. Prog. Biophys. Mol. Biol, 2006, 90, (1-3), 172-185.
26. Farmer, B. B.; Mancina, M.; Williams, E. S.; Watanabe, A. M., Isolation of calcium tolerant myocytes from adult rat hearts: review of the literature and description of a method. Life Sci, 1983, 33, (1), 1-18.
27. Fukuhiro, Y.; Wowk, M.; Ou, R.; Rosenfeldt, F.; Pepe, S., Cardioplegic strategies for calcium control: low Ca (2+), high Mg (2+), citrate, or Na (+)/H (+) exchange inhibitor HOE-642. Circulation, 2000, 102, (19 Suppl 3), III319-325.
28. Franzini-Armstrong, C.; Protasi, F.; Ramesh, V., Comparative ultrastructure of Ca2+ release units in skeletal and cardiac muscle. Ann. NY. Acad. Sci, 1998, 853, 20-30.
29. Brochet, D. X. P.; Yang, D.; Di Maio, A.; Lederer, W. J.; Franzini-Armstrong, C.; Cheng, H., Ca2+ blinks: rapid nanoscopic store calcium signaling. Proc. Natl. Acad. Sci. USA, 2005, 102, (8), 3099-3104.
30. Cheng, H.; Lederer, M.; Xiao, R.; Gomez, A.; Zhou, Y.; Ziman, B.; Spurgeon, H.; Lakatta, E.; Lederer, W., Excitation-contraction coupling in heart: new insights from Ca2+ sparks. Cell. Calcium, 1996, 20, (2), 129-140.
31. Bers, D., Calcium fluxes involved in control of cardiac myocyte contraction. Circ. Res., 2000, 87, (4), 275.
32. Balshaw, D. M.; Xu, L.; Yamaguchi, N.; Pasek, D. A.; Meissner, G., Calmodulin binding and inhibition of cardiac muscle calcium release channel (ryanodine receptor). J. Biol. Chem, 2001, 276, (23), 20144-20153.
33. Yamaguchi, N.; Xu, L.; Pasek, D. A.; Evans, K. E.; Meissner, G., Molecular basis of calmodulin binding to cardiac muscle Ca (2+) release channel (ryanodine receptor). J. Biol. Chem, 2003, 278, (26), 23480-23486.
34. Yamaguchi, N.; Takahashi, N.; Xu, L.; Smithies, O.; Meissner, G., Early cardiac hypertrophy in mice with impaired calmodulin regulation of cardiac muscle Ca release channel. J. Clin. Invest, 2007, 117, (5), 1344-1353.
35. Lanner, J. T.; Georgiou, D. K.; Joshi, A. D.; Hamilton, S. L., Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb. Perspect. Biol, 2010, 2, (11), a003996.
36. Sun, J.; Yamaguchi, N.; Xu, L.; Eu, J. P.; Stamler, J. S.; Meissner, G., Regulation of the cardiac muscle ryanodine receptor by O (2) tension and S-nitrosoglutathione. Biochemistry, 2008, 47, (52), 13985-13990.
37. Jayaraman, T.; Brillantes, A. M.; Timerman, A. P.; Fleischer, S.; Erdjument-Bromage, H.; Tempst, P.; Marks, A. R., FK506 binding protein associated with the calcium release channel (ryanodine receptor). J. Biol. Chem., 1992, 267, (14), 9474-9477.
38. Timerman, A. P.; Ogunbumni, E.; Freund, E.; Wiederrecht, G.; Marks, A. R.; Fleischer, S., The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. J. Biol. Chem., 1993, 268, (31), 22992-22999.
39. McCall, E.; Li, L.; Satoh, H.; Shannon, T. R.; Blatter, L. A.; Bers, D. M., Effects of FK-506 on contraction and Ca2+ transients in rat cardiac myocytes. Circ. Res., 1996, 79, (6), 1110-1121.
40. Miller, S. L.; Currie, S.; Loughrey, C. M.; Kettlewell, S.; Seidler, T.; Reynolds, D. F.; Hasenfuss, G.; Smith, G. L., Effects of calsequestrin overexpression on excitation-contraction coupling in isolated rabbit cardiomyocytes. Cardiovasc. Res., 2005, 67, (4), 667-677.
41. Gyorke, I.; Hester, N.; Jones, L. R.; Gyorke, S., The role of calsequestrin, triadin, and junctin in conferring cardiac ryanodine receptor responsiveness to luminal calcium. Biophys. J., 2004, 86, (4), 2121-2128.
42. Gergs, U.; Berndt, T.; Buskase, J.; Jones, L. R.; Kirchhefer, U.; Muller, F. U.; Schluter, K. D.; Schmitz, W.; Neumann, J., On the role of junctin in cardiac Ca2+ handling, contractility, and heart failure. Am. J. Physiol. Heart Circ. Physiol., 2007, 293, (1), H728-734.
43. Terentyev, D.; Cala, S. E.; Houle, T. D.; Viatchenko-Karpinski, S.; Gyorke, I.; Terentyeva, R.; Williams, S. C.; Gyorke, S., Triadin overexpression stimulates excitation-contraction coupling and increases predisposition to cellular arrhythmia in cardiac myocytes. Circ. Res., 2005, 96, (6), 651-658.
44. Prasad, V.; Okunade, G. W.; Miller, M. L.; Shull, G. E., Phenotypes of SERCA and PMCA knockout mice. Biochem. Biophys. Res. Commun., 2004, 322, (4), 1192-1203.
45. Cartwright, E.; Oceandy, D.; Neyses, L., Physiological implications of the interaction between the plasma membrane calcium pump and nNOS. Pflügers. Arch. Eur. J. Physiol., 2009, 457, (3), 665-671.
46. Bers, D. M.; Ginsburg, K. S., Na: Ca stoichiometry and cytosolic Cadependent activation of NCX in intact cardiomyocytes. Ann. N. Y. Acad. Sci., 2007, 1099, 326-338.
47. Henderson, S. A.; Goldhaber, J. I.; So, J. M.; Han, T.; Motter, C.; Ngo, A.; Chantawansri, C.; Ritter, M. R.; Friedlander, M.; Nicoll, D. A.; Frank, J. S.; Jordan, M. C.; Roos, K. P.; Ross, R. S.; Philipson, K. D., Functional Adult Myocardium in the Absence of Na+-Ca2+ Exchange. Circ. Res., 2004, 95, (6), 604-611.
48. Wakimoto, K.; Kobayashi, K.; Kuro, O. M.; Yao, A.; Iwamoto, T.; Yanaka, N.; Kita, S.; Nishida, A.; Azuma, S.; Toyoda, Y.; Omori, K.; Imahie, H.; Oka, T.; Kudoh, S.; Kohmoto, O.; Yazaki, Y.; Shigekawa, M.; Imai, Y.; Nabeshima, Y.; Komuro, I., Targeted disruption of Na+/Ca2+ exchanger gene leads to cardiomyocyte apoptosis and defects in heartbeat. J. Biol. Chem., 2000, 275, (47), 36991-36998.
49. Ohtsuka, M.; Takano, H.; Suzuki, M.; Zou, Y.; Akazawa, H.; Tamagawa, M.; Wakimoto, K.; Nakaya, H.; Komuro, I., Role of Na+-Ca2+ exchanger in myocardial ischemia/reperfusion injury: evaluation using a heterozygous Na+-Ca2+ exchanger knockout mouse model. Biochem. Biophys. Res. Commun., 2004, 314, (3), 849-853.
50. Wei, G. Z.; Zhou, J. J.; Wang, B.; Wu, F.; Bi, H.; Wang, Y. M.; Yi, D. H.; Yu, S. Q.; Pei, J. M., Diastolic Ca2+ overload caused by Na+/Ca2+ exchanger during the first minutes of reperfusion results in continued myocardial stunning. Eur. J. Pharmacol., 2007, 572, (1), 1-11.
51. Eigel, B. N.; Hadley, R. W., Antisense inhibition of Na+/Ca2+ exchange during anoxia/reoxygenation in ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol., 2001, 281, (5), H2184-2190.
52. Hattori, Y.; Matsuda, N.; Kimura, J.; Ishitani, T.; Tamada, A.; Gando, S.; Kemmotsu, O.; Kanno, M., Diminished function and expression of the cardiac Na+-Ca2+ exchanger in diabetic rats: implication in Ca2+ overload. J. Physiol., 2000, 527. Pt. 1, 85-94.
53. Dally, S.; Corvazier, E.; Bredoux, R.; Bobe, R.; Enouf, J., Multiple and diverse coexpression, location, and regulation of additional SERCA2 and SERCA3 isoforms in nonfailing and failing human heart. J. Mol. Cell. Cardiol., 2010, 48, (4), 633-644.
54. Shanmugam, M.; Molina, C. E.; Gao, S.; Severac-Bastide, R.; Fischmeister, R.; Babu, G. J., Decreased sarcolipin protein expression and enhanced sarco (endo) plasmic reticulum Ca2+ uptake in human atrial fibrillation. Biochem. Biophys. Res. Commun, 2011, 410, (1), 97-101.
55. Traaseth, N. J.; Ha, K. N.; Verardi, R.; Shi, L.; Buffy, J. J.; Masterson, L. R.; Veglia, G., Structural and dynamic basis of phospholamban and sarcolipin inhibition of Ca (2+)-ATPase. Biochemistry, 2008, 47, (1), 3-13.
56. Morita, T.; Hussain, D.; Asahi, M.; Tsuda, T.; Kurzydlowski, K.; Toyoshima, C.; Maclennan, D. H., Interaction sites among phospholamban, sarcolipin, and the sarco (endo) plasmic reticulum Ca (2+)-ATPase. Biochem. Biophys. Res. Commun., 2008, 369, (1), 188-194.
57. Brittsan, A. G.; Kranias, E. G., Phospholamban and cardiac contractile function. J. Mol. Cell. Cardiol, 2000, 32, (12), 2131-2139.
58. Katz, A. M., Discovery of phospholamban. A personal history. Ann. N. Y. Acad. Sci., 1998, 853, 9-19.
59. MacLennan, D. H.; Kranias, E. G., Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell. Biol, 2003, 4, (7), 566-577.
60. Arkin, I. T.; Adams, P. D.; Brunger, A. T.; Smith, S. O.; Engelman, D. M., Structural perspectives of phospholamban, a helical transmembrane pentamer. Annu. Rev. Biophys. Biomol. Struct., 1997, 26, 157-179.
61. Vittone, L.; Mundina-Weilenmann, C.; Mattiazzi, A., Phospholamban phosphorylation by CaMKII under pathophysiological conditions. Front. Biosci, 2008, 13, 5988-6005.
62. Ghimire, H.; Abu-Baker, S.; Sahu, I. D.; Zhou, A.; Mayo, D. J.; Lee, R. T.; Lorigan, G. A., Probing the helical tilt and dynamic properties of membranebound phospholamban in magnetically aligned bicelles using electron paramagnetic resonance spectroscopy. Biochim. Biophys. Acta, 2012, 1818, (3), 645-650.
63. Kelly, E. M.; Hou, Z.; Bossuyt, J.; Bers, D. M.; Robia, S. L., Phospholamban oligomerization, quaternary structure, and sarco (endo) plasmic reticulum calcium ATPase binding measured by fluorescence resonance energy transfer in living cells. J. Biol. Chem., 2008, 283, (18), 12202-12211.
64. Oxenoid, K.; Rice, A. J.; Chou, J. J., Comparing the structure and dynamics of phospholamban pentamer in its unphosphorylated and pseudophosphorylated states. P rotein Sci., 2007, 16, (9), 1977-1983.
65. Froehlich, J. P.; Mahaney, J. E.; Keceli, G.; Pavlos, C. M.; Goldstein, R.; Redwood, A. J.; Sumbilla, C.; Lee, D. I.; Tocchetti, C. G.; Kass, D. A., Phospholamban Thiols Play a Central Role in Activation of the Cardiac Muscle Sarcoplasmic Reticulum Calcium Pump by Nitroxyl. Biochemistry, 2008, 47, (50), 13150-13152.
66. Lukyanenko, V.; Chikando, A.; Lederer, W. J., Mitochondria in cardiomyocyte Ca2+ signaling. Inter. J. Biochem. & Cell. Biol., 2009, 41, (10), 1957-1971.
67. Rizzuto, R.; Marchi, S.; Bonora, M.; Aguiari, P.; Bononi, A.; Stefani, D. D.; Giorgi, C.; Leo, S.; Rimessi, A.; Siviero, R.; Zecchini, E.; Pinton, P., Ca2+ transfer from the ER to mitochondria: When, how and why. BBA - Bioenergetics, 2009, 1787, (11), 1342-1351.
68. Hajnóczky, G.; Csordás, G., Calcium Signalling: Fishing Out Molecules of Mitochondrial Calcium Transport. Curr. Biol.: CB, 2010, 20, (20), R888-R891.
69. Hoppe, U. C., Mitochondrial calcium channels. FEBS Lett., 2010, 584, (10), 1975-1981.
70. Sloan, R. C.; Moukdar, F.; Frasier, C. R.; Patel, H. D.; Bostian, P. A.; Lust, R. M.; Brown, D. A., Mitochondrial permeability transition in the diabetic heart: contributions of thiol redox state and mitochondrial calcium to augmented reperfusion injury. J. Mol. Cell. Cardiol., 2012, 52, (5), 1009-1018.
71. Twig, G.; Hyde, B.; Shirihai, O. S., Mitochondrial fusion, fission and autophagy as a quality control axis: the bioenergetic view. Biochim. Biophys. Acta, 2008, 1777, (9), 1092-1097.
72. Piquereau, J.; Caffin, F.; Novotova, M.; Prola, A.; Garnier, A.; Mateo, P.; Fortin, D.; Huynh le, H.; Nicolas, V.; Alavi, M. V.; Brenner, C.; Ventura-Clapier, R.; Veksler, V.; Joubert, F., Down-regulation of OPA1 alters mouse mitochondrial morphology, PTP function, and cardiac adaptation to pressure overload. Cardiovasc. Res., 2012, 94, (3), 408-417.
73. Ong, S. B.; Subrayan, S.; Lim, S. Y.; Yellon, D. M.; Davidson, S. M.; Hausenloy, D. J., Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation, 2010, 121, (18), 2012-2022.
74. Hausenloy, D. J.; Yellon, D. M., Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail. Rev., 2007, 12, (3-4), 217-234.
75. Mensah, K.; Mocanu, M. M.; Yellon, D. M., Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten. J. Am. Coll. Cardiol., 2005, 45, (8), 1287-1291.
76. Hausenloy, D. J.; Yellon, D. M., Cardioprotective growth factors. Cardiovasc. Res, 2009, 83, (2), 179-194.
77. Montero, J. C.; Yuste, L.; Diaz-Rodriguez, E.; Esparis-Ogando, A.; Pandiella, A., Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme. Mol. Cell. Neurosci., 2000, 16, (5), 631-648.
78. Shi, W.; Chen, H.; Sun, J.; Buckley, S.; Zhao, J.; Anderson, K.; Williams, R.; Warburton, D., TACE is required for fetal murine cardiac development and modeling. Dev. Biol., 2003, 26, (2), 371-380.
79. Shirakabe, K.; Wakatsuki, S.; Kurisaki, T.; Fujisawa-Sehara, A., Roles of Meltrin beta/ADAM19 in the processing of neuregulin. J. Biol. Chem., 2001, 276, (12), 9352-9358.
80. Falls, D. L., Neuregulins: functions, forms, and signaling strategies. Exp. Cell. Res, 2003, 284, (1), 14-30.
81. Meyer, D.; Birchmeier, C., Multiple essential functions of neuregulin in development. Nature, 1995, 378, (6555), 386-390.
82. Lee, K. F.; Simon, H.; Chen, H.; Bates, B.; Hung, M. C.; Hauser, C., Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature, 1995, 378, (6555), 394-398.
83. Gassmann, M.; Casagranda, F.; Orioli, D.; Simon, H.; Lai, C.; Klein, R.; Lemke, G., Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature, 1995, 378, (6555), 390-394.
84. Erickson, S.; O'Shea, K.; Ghaboosi, N.; Loverro, L.; Frantz, G.; Bauer, M.; Lu, L.; Moore, M., ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development, 1997, 124, (24), 4999-5011.
85. Lemmens, K.; Segers, V. F.; Demolder, M.; De Keulenaer, G. W., Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. J. Biol. Chem., 2006, 281, (28), 19469-19477.
86. Hedhli, N.; Huang, Q.; Kalinowski, A.; Palmeri, M.; Hu, X.; Russell, R. R.; Russell, K. S., Endothelium-Derived Neuregulin Protects the Heart Against Ischemic Injury. Circulation, 2011, 123, (20), 2254-2262.
87. Zhao, Y. Y.; Sawyer, D. R.; Baliga, R. R.; Opel, D. J.; Han, X.; Marchionni, M. A.; Kelly, R. A., Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J. Biol. Chem., 1998, 273, (17), 10261-10269.
88. Burgess, A.; Cho, H.; Eigenbrot, C.; Ferguson, K.; Garrett, T.; Leahy, D.; Lemmon, M.; Sliwkowski, M.; Ward, C; Yokoyama, S., An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell, 2003, 12, (3), 541-552.
89. Pentassuglia, L.; Sawyer, D. B., The role of Neuregulin-1beta/ErbB signaling in the heart. Exp. Cell. Res, 2009, 315, (4), 627-637.
90. Zhenggang, J.; Zhou, M., Neuregulin Signaling and Heart Failure. Curr. Heart Fail. Rep, 2010, 7, 42-47.
91. Giraud, M.; Fluck, M.; Zuppinger, C; Suter, T., Expressional reprogramming of servival pathways in rat cardiocytes by neuregulin-1beta. J. Appl. Physiol, 2005, 99, (1), 313-322.
92. Baliga, R. R.; Pimental, D. R.; Zhao, Y. Y.; Simmons, W. W.; Marchionni, M. A.; Sawyer, D. B.; Kelly, R. A., NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70 (S6K), and MEK-MAPK-RSK. Am. J. Physiol, 1999, 277, (5 Pt 2), H2026-2037.
93. Kuramochi, Y; Guo, X.; Sawyer, D. B., Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J. Mol. Cell. Cardiol, 2006, 41, (2), 228-235.
94. Zhang, S.; Weinheimer, C; Courtois, M.; Kovacs, A.; Zhang, C. E.; Cheng, A. M.; Wang, Y; Muslin, A. J., The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J. Clin. Invest, 2003, 111, (6), 833-841.
95. Pero, S. C.; Shukla, G. S.; Cookson, M. M.; Flemer, S., Jr.; Krag, D. N., Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells. Br. J. Cancer, 2007, 96, (10), 1520-1525.
96. Obreztchikova, M.; Elouardighi, H.; Ho, M.; Wilson, B. A.; Gertsberg, Z.; Steinberg, S. F., Distinct signaling functions for Shc isoforms in the heart. J. Biol. Chem, 2006, 281, (29), 20197-20204.
97. Cote, G. M.; Miller, T. A.; Lebrasseur, N. K.; Kuramochi, Y; Sawyer, D. B., Neuregulin-1 alpha and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Exp. Cell. Res., 2005, 311, (1), 135-146.
98. Fukazawa, R.; Miller, T. A.; Kuramochi, Y; Frantz, S.; Kim, YD.; Marchionni, M. A.; Kelly, R. A.; Sawyer, D. B., Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J. Mol. Cell. Cardiol, 2003, 35, (12), 1473-1479.
99. Lemmens, K.; Fransen, P.; Sys, S. U.; Brutsaert, D. L.; De Keulenaer, G. W., Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase. Circulation, 2004, 109, (3), 324-326.
100. Mansour, H.; Tombe, P.d.; Samarel, A.; Russell, B., Restoration of resting sarcomere lenght after uniaxial static strain is regulated by protein kinase C epsilon and focal adhesion kinase. Circ. Res., 2004, 94, (5), 642-649.
101. Kuppuswamy, D., Importance of integrin signaling in myocyte growth and survival. Circ. Res., 2002, 90, (12), 1240-1242.
102. Feldman, A. M.; Lorell, B. H.; Reis, S. E., Trastuzumab in the treatment of metastatic breast cancer anticancer therapy versus cardiotoxicity. Circulation, 2000, 102, (3), 272-274.
103. Ozcelik, C; Erdmann, B.; Pilz, B.; Wettschureck, N; Britsch, S.; Hubner, N; Chien, K. R.; Birchmeier, C; Garratt, A. N., Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. USA, 2002, 99, (13), 8880-8885.
104. Keulenaer, G. D.; Doggen, K.; Lemmens, K., The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ. Res., 2010, 106, (1), 35-46.
105. Lemmens, K.; Doggen, K.; De Keulenaer, G. W., Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease: Implications for Therapy of Heart Failure. Circulation, 2007, 116, (8), 954-960.
106. Massion, P.; Feron, O.; Dessy, C; Balligand, J., Nitric oxide and cardiac function: ten years after, and continuing. Circ. Res., 2003, 93, 388-398.
107. Okoshi, K.; Nakayama, M.; Yan, X.; Okoshi, M. P.; Schuldt, A. J.; Marchionni, M. A.; Lorell, B. H., Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion. Circulation, 2004, 110, (6), 713-717.
108. Brero, A.; Ramella, R.; Fitou, A.; Dati, C; Alloatti, G.; Gallo, M. P.; Levi, R., Neuregulin-1 β1 rapidly modulates nitric oxide synthesis and calcium handling in rat cardiomyocytes. Cardiovas. Res., 2010, 88, (3), 443-452.
109. Xu, Y; Li, X.; Zhou, M., Neuregulin-1/ErbB signaling: a druggable target for treating heart failure. Curr. Opin. Pharmacol, 2009, 9, (2), 214-219.
110. Timolati, F.; Ott, D.; Pentassuglia, L.; Giraud, M.-N; Perriard, J.-C; Suter, T. M.; Zuppinger, C, Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J. Mol Cell. Cardiol, 2006, 41, (5), 845-854.
111. Liu, X.; Gu, X.; Li, Z.; Li, X.; Li, H.; Chang, J.; Chen, P.; Jin, J.; Xi, B.; Chen, D.; Lai, D.; Graham, R.; Zhou, M., Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J. Am. Coll. Cardiol, 2006, 48, 1438-1447.
112. Griffiths, E. J., Mitochondrial calcium transport in the heart: physiological and pathological roles. J. Mol. Cell. Cardiol, 2009, 46, (6), 789-803.
113. Halestrap, A.; Clarke, S.; Javadov, S., Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc. Res., 2004, 61, (3), 372-385.
114. Miyata, H.; Silverman, H. S.; Sollott, S. J.; Lakatta, E. G.; Stern, M. D.; Hansford, R. G., Measurement of mitochondrial free Ca2+ concentration in living single rat cardiac myocytes. Am. J. Physiol, 1991, 261, (4 Pt 2), H1123-1134.
115. Ruiz-Meana, M.; Abellan, A.; Miro-Casas, E.; Agullo, E.; Garcia-Dorado, D., Role of sarcoplasmic reticulum in mitochondrial permeability transition and cardiomyocyte death during reperfusion. Am. J. Physiol. Heart Circ. Physiol, 2009, 297, (4), H1281-1289.
116. Halestrap, A., What is the mitochondrial permeability transition pore? J. Mol. Cell. Cardiol, 2009, 46, (6), 821-831.
117. Garlid, K. D.; Costa, A. D.; Quinlan, C. L.; Pierre, S. V.; Dos Santos, P., Cardioprotective signaling to mitochondria. J. Mol. Cell. Cardiol, 2009, 46, (6), 858-866.
118. Juhaszova, M.; Zorov, D. B.; Kim, S. H.; Pepe, S.; Fu, Q.; Fishbein, K. W.; Ziman, B. D.; Wang, S.; Ytrehus, K.; Antos, C. L.; Olson, E. N.; Sollott, S. J., Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J. Clin. Invest, 2004, 113, (11), 1535-1549.
119. Miura, GSK-3β a Therapeutic Target for Cardiomyocyte Protection. Circ. J., 2009, 73(7), 1184-1192.
120. Garcia-Dorado, D.; Agulló, L.; Sartorio, C; Ruiz-Meana, M., Myocardial protection against reperfusion injury: the cGMP pathway. Thromb. Haemost, 2009, 101, (4), 635-642.
121. Kuramochi, Y; Cote, G.; Guo, X.; Lebrasseur, N; Cui, L.; Liao, R.; Sawyer, D., Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. J. Biol. Chem., 2004, 279, (49), 1141-1147.
122. Lewis, K.; Li, C; Perrin, M. H.; Blount, A.; Kunitake, K.; Donaldson, C; Vaughan, J.; Reyes, T. M.; Gulyas, J.; Fischer, W.; Bilezikjian, L.; Rivier, J.; Sawchenko, P. E.; Vale, W. W., Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. USA, 2001, 98, (13), 7570-7575.
123. Reyes, T. M.; Lewis, K.; Perrin, M. H.; Kunitake, K. S.; Vaughan, J.; Arias, C. A.; Hogenesch, J. B.; Gulyas, J.; Rivier, J.; Vale, W. W.; Sawchenko, P. E., Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. USA, 2001, 98, (5), 2843-2848.
124. Vaughan, J.; Donaldson, C; Bittencourt, J.; Perrin, M. H.; Lewis, K.; Sutton, S.; Chan, R.; Turnbull, A. V.; Lovejoy, D.; Rivier, C, Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropinreleasing factor. Nature, 1995, 378, (6554), 287-292.
125. Takahashi, K.; Totsune, K.; Murakami, O.; Shibahara, S., Urocortins as cardiovascular peptides. Peptides, 2004, 25, (10), 1723-1731.
126. Emeto, T. I.; Moxon, J. V; Rush, C; Woodward, L.; Golledge, J., Relevance of urocortins to cardiovascular disease. J. Mol. Cell. Cardiol, 2011, 51, (3), 299-307.
127. Brar, B. K.; Jonassen, A. K.; Egorina, E. M.; Chen, A.; Negro, A.; Perrin, M. H.; Mjos, O. D.; Latchman, D. S.; Lee, K. F.; Vale, W., Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology, 2004, 145, (1), 24-35; discussion 21-23.
128. Brar, B. K.; Jonassen, A. K.; Stephanou, A.; Santilli, G.; Railson, J.; Knight, R. A.; Yellon, D. M.; Latchman, D. S., Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J. Biol. Chem., 2000, 275, (12), 8508-8514.
129. Latchman, D. S., Urocortin protects against ischemic injury via a MAPK-dependent pathway. Trends Cardiovasc. Med., 2001, 11, (5), 167-169.
130. Schulman, D.; Latchman, D. S.; Yellon, D. M., Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. Am. J. Physiol. Heart. Circ. Physiol, 2002, 283, (4), H1481-1488.
131. Townsend, P. A.; Davidson, S. M.; Clarke, S. J.; Khaliulin, I.; Carroll, C. J.; Scarabelli, T. M.; Knight, R. A.; Stephanou, A.; Latchman, D. S.; Halestrap, A. P., Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress. Am. J. Physiol. Heart Circ. Physiol, 2007, 293, (2), H928-938.
132. Yang, L. Z.; Kockskamper, J.; Khan, S.; Suarez, J.; Walther, S.; Doleschal, B.; Unterer, G.; Khafaga, M.; Machler, H.; Heinzel, F. R.; Dillmann, W. H.; Pieske, B.; Spiess, J., cAMP-and Ca (2) (+)/calmodulin-dependent protein kinases mediate inotropic, lusitropic and arrhythmogenic effects of urocortin 2 in mouse ventricular myocytes. Br. J. Pharmacol, 2011, 162, (2), 544-556.
133. Calderon-Sanchez, E. M.; Ruiz-Hurtado, G.; Smani, T; Delgado, C; Benitah, J. P.; Gomez, A. M.; Ordonez, A., Cardioprotective action of urocortin in postconditioning involves recovery of intracellular calcium handling. Cell. Calcium, 2011, 50, (1), 84-90.
134. Potter, L. R.; Yoder, A. R.; Flora, D. R.; Antos, L. K.; Dickey, D. M., Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb. Exp. Pharmacol, 2009, (191), 341-366.
135. Rose, R. A.; Giles, W. R., Natriuretic peptide C receptor signalling in the heart and vasculature. J. Physiol, 2008, 586, (2), 353-366.
136. Rose, R. A.; Lomax, A. E.; Kondo, C. S.; Anand-Srivastava, M. B.; Giles, W. R., Effects of C-type natriuretic peptide on ionic currents in mouse sinoatrial node: a role for the NPR-C receptor. Am. J. Physiol. Heart Circ. Physiol, 2004, 286, (5), H1970-1977.
137. Hobbs, A.; Foster, P.; Prescott, C.; Scotland, R.; Ahluwalia, A., Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endotheliumderived C-type natriuretic peptide. Circulation, 2004, 110, (10), 1231-1235.
138. Scotland, R. S.; Ahluwalia, A.; Hobbs, A. J., C-type natriuretic peptide in vascular physiology and disease. Pharmacol. Ther., 2005, 105, (2), 85-93.
139. Springer, J.; Azer, J.; Hua, R.; Robbins, C.; Adamczyk, A.; McBoyle, S.; Bissell, M. B.; Rose, R. A., The natriuretic peptides BNP and CNP increase heart rate and electrical conduction by stimulating ionic currents in the sinoatrial node and atrial myocardium following activation of guanylyl cyclase-linked natriuretic peptide receptors. J. Mol. Cell. Cardiol., 2012, 52, (5), 1122-1134.
140. Gareau, J. R.; Lima, C. D., The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat. Rev. Mol. Cell. Biol., 2010, 11, (12), 861-871.
141. Kho, C.; Lee, A.; Jeong, D.; Oh, J. G.; Chaanine, A. H.; Kizana, E.; Park, W. J.; Hajjar, R. J., SUMO1-dependent modulation of SERCA2a in heart failure. Nature, 2011, 477, (7366), 601-605.
142. Meyer, M.; Schillinger, W.; Pieske, B.; Holubarsch, C.; Heilmann, C.; Posival, H.; Kuwajima, G.; Mikoshiba, K.; Just, H.; Hasenfuss, G.; al., e., Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation, 1995, 15, 92(4), 778-784.
143. Wang, J.; Feng, X. H.; Schwartz, R. J., SUMO-1 modification activated GATA4-dependent cardiogenic gene activity. J. Biol. Chem., 2004, 279, (47), 49091-49098.
144. Wang, J.; Li, A.; Wang, Z.; Feng, X.; Olson, E. N.; Schwartz, R. J., Myocardin sumoylation transactivates cardiogenic genes in pluripotent 10T1/2 fibroblasts. Mol. Cell. Biol., 2007, 27, (2), 622-632.
145. Wang, J.; Zhang, H.; Iyer, D.; Feng, X. H.; Schwartz, R. J., Regulation of cardiac specific nkx2.5 gene activity by small ubiquitin-like modifier. J. Biol. Chem., 2008, 283, (34), 23235-23243.
146. Kim, E. Y.; Chen, L.; Ma, Y.; Yu, W.; Chang, J.; Moskowitz, I. P.; Wang, J., Expression of sumoylation deficient Nkx2.5 mutant in Nkx2.5 haploinsufficient mice leads to congenital heart defects. PLoS ONE, 2011, 6, (6), e20803.
147. Kim, E. Y.; Chen, L.; Ma, Y.; Yu, W.; Chang, J.; Moskowitz, I. P.; Wang, J., Enhanced desumoylation in murine hearts by overexpressed SENP2 leads to congenital heart defects and cardiac dysfunction. J. Mol. Cell. Cardiol., 2011.
148. Harder, Z.; Zunino, R.; McBride, H., Sumo1 conjugates mitochondrial substrates and participates in mitochondrial fission. Curr. Biol., 2004, 14, (4), 340-345.
149. Zunino, R.; Schauss, A.; Rippstein, P.; Andrade-Navarro, M.; McBride, H., The SUMO protease SENP5 is required to maintain mitochondrial morphology and function.. J. Cell. Sci., 2007, 120, 1178-1188.
150. Hom, J.; Yu, T.; Yoon, Y.; Porter, G.; Sheu, S. S., Regulation of mitochondrial fission by intracellular Ca2+ in rat ventricular myocytes. Biochim. Biophys. Acta, 2010, 1797, (6-7), 913-921.
151. Parra, V.; Eisner, V.; Chiong, M.; Criollo, A.; Moraga, F.; Garcia, A.; Hartel, S.; Jaimovich, E.; Zorzano, A.; Hidalgo, C.; Lavandero, S., Changes in mitochondrial dynamics during ceramide-induced cardiomyocyte early apoptosis. Cardiovasc. Res., 2008, 77, (2), 387-397.
152. Zungu, M.; Schisler, J.; Willis, M., All the little pieces. Regulation of mitochondrial fusion and fission by ubiquitin and small ubiquitin-like modifer and their potential relevance in the heart. Circ. J., 2011, 75, 2513-2521.
153. de Bold, A. J., Atrial natriuretic factor: an overview. Fed. Proc., 1986, 45, (7), 2081-2085.
154. McGrath, M. F.; de Bold, M. L.; de Bold, A. J. The endocrine function of the heart. Trends Endocrinol. Metab., 2005, 16(10), 469-477.
155. Pandey, K. N., Emerging Roles of Natriuretic Peptides and their Receptors in Pathophysiology of Hypertension and Cardiovascular Regulation. J. Am. Soc. Hypertens, 2008, 2(4), 210-226